Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Chia-Chih Kuo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Alcoholism. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background and Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have shown promise in reducing alcohol consumption, but their impact on clinical outcomes in patients with alcohol use disorder (AUD) remains unclear. We investigated the association between GLP‐1RAs and the development and progression of alcohol‐related liver disease (ArLD) in patients with AUD.
Methods
Using the TriNetX Research Network, we conducted two retrospective cohort studies comparing GLP‐1RAs versus dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in patients with type 2 diabetes. The first cohort included patients with AUD but without ArLD ( n = 7132 after propensity score matching), while the second comprised patients with established ArLD ( n = 1896 after matching). Primary outcomes were incident ArLD in the AUD cohort and hepatic decompensation in the ArLD cohort.
Results
In the AUD cohort (median follow‐up: 63.2 months), GLP‐1RA users showed significantly lower risks of developing ArLD compared to DPP‐4i users (incidence rate: 6.0 vs. 8.7 per 1000 person‐years; HR: 0.62, 95% CI: 0.44–0.87, p = 0.006). GLP‐1RAs were also associated with reduced risks of all‐cause mortality (HR: 0.53, p < 0.001). In the ArLD cohort (median follow‐up: 28.2 months), GLP‐1RA users demonstrated lower risks of hepatic decompensation (incidence rate: 39.5 vs. 51.4 per 1000 person‐years; HR: 0.66, 95% CI: 0.51–0.85, p = 0.001) and all‐cause mortality (HR: 0.53, p < 0.001) compared to DPP‐4i users.
Conclusions
GLP‐1RAs were associated with reduced risks of developing and progressing ArLD in patients with AUD, suggesting potential therapeutic benefits in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Physical Medicine and Rehabilitation, Chi Mei Medical Center, Tainan, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
- Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
ORCID-Profile: Chih-Cheng Lai
Zitieren
APA
Kuo, C. C., Li, C. H., Chuang, M. H., Huang, P. Y., Kuo, H. T., & Lai, C. C. (2025). Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70007
Vancouver
Kuo CC, Li CH, Chuang MH, Huang PY, Kuo HT, Lai CC. Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70007
BibTeX
@article{Kuo2025,
author = {Kuo, Chia-Chih and Li, Chun-Hsien and Chuang, Min-Hsiang and Huang, Po-Yu and Kuo, Hsing-Tao and Lai, Chih-Cheng},
title = {Impact of GLP ‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70007}
}
EUVIMED